{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:49Z","timestamp":1759017889726,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lexicon Pharmaceuticals, Inc"},{"name":"Lexicon Pharmaceuticals, Inc."},{"name":"Lexicon Pharmaceuticals, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clinthera.2019.06.013","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T17:31:09Z","timestamp":1563384669000},"page":"1716-1723.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues"],"prefix":"10.1016","volume":"41","author":[{"given":"Vijay N.","family":"Joish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Perez-Olle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Lapuerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Dharba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Zacks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.06.013_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2019.06.013_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/CCO.0b013e328353d7ba","article-title":"Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches","volume":"24","author":"Oberg","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clinthera.2019.06.013_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2019.06.013_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00001610-200205000-00004","article-title":"Carcinoid tumors and syndrome","volume":"25","author":"McCormick","year":"2002","journal-title":"Gastroenterol Nurs"},{"key":"10.1016\/j.clinthera.2019.06.013_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","article-title":"An analysis of 8305 cases of carcinoid tumors","volume":"79","author":"Modlin","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2019.06.013_bib6","doi-asserted-by":"crossref","first-page":"973946","DOI":"10.1155\/2012\/973946","article-title":"Treatment of neuroendocrine tumor liver metastases","volume":"2012","author":"Lewis","year":"2012","journal-title":"Int J Hepatol"},{"year":"2017","series-title":"Carcinoid Syndrome","author":"Pandit","key":"10.1016\/j.clinthera.2019.06.013_bib7"},{"key":"10.1016\/j.clinthera.2019.06.013_bib8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.06.013_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ahj.2014.03.018","article-title":"Carcinoid heart disease: current understanding and future directions","volume":"167","author":"Patel","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2019.06.013_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCIMAGING.109.886846","article-title":"Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI","volume":"3","author":"Bhattacharya","year":"2010","journal-title":"Circ Cardiovasc Imag"},{"key":"10.1016\/j.clinthera.2019.06.013_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment\u2014\u201csomething in the way it moves","volume":"101","author":"Grozinsky-Glasberg Sm Grossman","year":"2015","journal-title":"Neuroendocrinol"},{"key":"10.1016\/j.clinthera.2019.06.013_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2019.06.013_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021451","article-title":"Factors associated with progression of carcinoid heart disease","volume":"348","author":"M\u00f8ller","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.06.013_bib14","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.2217\/fon-2018-0129","article-title":"Economic analysis of inadequate symptom control in carcinoid syndrome in the United States","volume":"14","author":"Burton","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.clinthera.2019.06.013_bib15","doi-asserted-by":"crossref","first-page":"A552","DOI":"10.1016\/j.jval.2017.08.871","article-title":"Real-world resource use and costs of carcinoid heart disease in patients with neuroendocrine tumors: a retrospective Swedish study","volume":"20","author":"Bj\u00f6rstad","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.06.013_bib16","first-page":"1","article-title":"Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study","volume":"19","author":"Les\u00e9n","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clinthera.2019.06.013_bib17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2019.06.013_bib18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.clinthera.2019.06.013_bib19","unstructured":"Bureau of Labor Statistics. Consumer price index inflation calculator. Available at: https:\/\/www.bls.gov\/data\/inflation_calculator.htm. Accessed December 10, 2018."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:39Z","timestamp":1758963099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819303406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0149291819303406"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.06.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}